{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:47:37Z","timestamp":1771303657614,"version":"3.50.1"},"reference-count":35,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,2,1]]},"abstract":"<jats:p>A 29-yr-old woman with pituitary resistance to thyroid hormones (PRTH) was found to harbor a novel point mutation (T337A) on exon 9 of the thyroid hormone receptor \u03b2 (TR\u03b2) gene. She presented with symptoms and signs of hyperthyroidism and was successfully treated with 3,5,3\u2032-triiodothyroacetic acid (TRIAC) until the onset of pregnancy. This therapy was then discontinued in order to prevent TRIAC, a compound that crosses the placental barrier, from exerting adverse effects on normal fetal development. However, as the patient showed a recurrence of thyrotoxic features after TRIAC withdrawal, we sought to verify, by means of genetic analysis and hormone measurements, whether the fetus was also affected by RTH, in order to rapidly reinstitute TRIAC therapy, which could potentially be beneficial to both the mother and fetus. At 17 weeks gestation, fetal DNA was extracted from chorionic villi and was used as a template for PCR and restriction analysis together with direct sequencing of the TR\u03b2 gene. The results indicated that the fetus was also heterozygous for the T337A mutation. Accordingly, TRIAC treatment at a dose of 2.1 mg\/day was restarted at 20 weeks gestation. The mother rapidly became euthyroid, and the fetus grew normally up to 24 weeks gestation. At 29 weeks gestation mild growth retardation and fetal goiter were observed, prompting cordocentesis. Circulating fetal TSH was very high (287 mU\/L) with a markedly reduced TSH bioactivity (B\/I: 1.1 \u00b1 0.4 vs 12.7 \u00b1 1.2), while fetal FT4 concentrations were normal (8.7 pmol\/L; normal values in age-matched fetuses: 5\u201322 pmol\/L). Fetal FT3 levels were raised (7.1 pmo\/L; normal values in age-matched fetuses: &amp;lt;4 pmol\/L), as a consequence of 100% cross-reactivity of TRIAC in the FT3 assay method. To reduce the extremely high circulating TSH levels and fetal goiter, the dose of TRIAC was increased to 3.5 mg\/day. To monitor the possible intrauterine hypothyroidism, another cordocentesis was performed at 33 weeks gestation, showing that TSH levels were reduced by 50% (from 287 to 144 mU\/L). Furthermore, a simultaneous ultrasound examination revealed a clear reduction in fetal goiter. After this latter cordocentesis, acute complications occured, prompting delivery by cesarean section. The female neonate was critically ill, with multiple-organ failure and respiratory distress syndrome. In addition, a small goiter and biochemical features of hypothyroidism were noted transiently and probably related to the prematurity of the infant. At present, the baby is clinically euthyroid, without goiter, and only exhibits biochemical features of RTH. In summary, although further fetal studies in cases of RTH are necessary to determine whether elevated TSH levels with a markedly reduced bioactivity are a common finding, our data suggest transient biochemical hypothyroidism in RTH during fetal development. Furthermore, we advocate prenatal diagnosis of RTH and adequate treatment of the disease in case of maternal hyperthyroidism, to avoid fetal thyrotrope hyperplasia, reduce fetal goiter, and maintain maternal euthyroidism during pregnancy.<\/jats:p>","DOI":"10.1210\/jcem.84.2.5479","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:03:55Z","timestamp":1389200635000},"page":"405-410","source":"Crossref","is-referenced-by-count":37,"title":["Prenatal Diagnosis of Thyroid Hormone Resistance"],"prefix":"10.1210","volume":"84","author":[{"given":"C.","family":"Asteria","sequence":"first","affiliation":[{"name":"Institute of Endocrine Sciences, Inc. (C.A., L.P., R.R., D.M., P.B.P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Clinico Humanitas, Istituto Auxologico Italiano, IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Rajanayagam","sequence":"additional","affiliation":[{"name":"Department of Medicine (O.R., T.N.C., V.K.K.C.), University of Cambridge, U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. N.","family":"Collingwood","sequence":"additional","affiliation":[{"name":"Department of Medicine (O.R., T.N.C., V.K.K.C.), University of Cambridge, U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Persani","sequence":"additional","affiliation":[{"name":"Institute of Endocrine Sciences, Inc. (C.A., L.P., R.R., D.M., P.B.P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Clinico Humanitas, Istituto Auxologico Italiano, IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Romoli","sequence":"additional","affiliation":[{"name":"Institute of Endocrine Sciences, Inc. (C.A., L.P., R.R., D.M., P.B.P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Clinico Humanitas, Istituto Auxologico Italiano, IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mannavola","sequence":"additional","affiliation":[{"name":"Institute of Endocrine Sciences, Inc. (C.A., L.P., R.R., D.M., P.B.P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Clinico Humanitas, Istituto Auxologico Italiano, IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zamperini","sequence":"additional","affiliation":[{"name":"Department of Obstretics and Gynecology (P.Z.), Ospedale S. Paolo, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Buzi","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (F.B.), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ciralli","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care (F.C.), University of Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. K. K.","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Medicine (O.R., T.N.C., V.K.K.C.), University of Cambridge, U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beck-Peccoz","sequence":"additional","affiliation":[{"name":"Institute of Endocrine Sciences, Inc. (C.A., L.P., R.R., D.M., P.B.P.), University of Milan, Ospedale Maggiore IRCCS, Istituto Clinico Humanitas, Istituto Auxologico Italiano, IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071618582238300_R1","first-page":"384","article-title":"The syndromes of resistance to thyroid hormone.","volume":"14","author":"Refetoff","year":"1993","journal-title":"Endocr Rev"},{"key":"2020071618582238300_R2","author":"Beck-Peccoz","year":"1997"},{"key":"2020071618582238300_R3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI116474","article-title":"Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene.","volume":"91","author":"Weiss","year":"1993","journal-title":"J Clin Invest"},{"key":"2020071618582238300_R4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1172\/JCI117362","article-title":"Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the hormone receptor \u03b2 gene.","volume":"94","author":"Adams","year":"1994","journal-title":"J Clin Invest"},{"key":"2020071618582238300_R5","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1210\/jcem.80.11.7593433","article-title":"Do clinical manifestation of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-\u03b2 receptors?","volume":"80","author":"Hayashi","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618582238300_R6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.7326\/0003-4819-123-8-199510150-00002","article-title":"Genetic and clinical features in 42 kindreds with resistance to thyroid hormone.","volume":"123","author":"Brucker-Davis","year":"1995","journal-title":"Ann Intern Med"},{"key":"2020071618582238300_R7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archinte.1982.00340200041011","article-title":"Hyperthyroidism caused by inappropriate thyrotropin secretion.","volume":"142","author":"Spanheimer","year":"1982","journal-title":"Arch Intern Med"},{"key":"2020071618582238300_R8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF03346968","article-title":"Familial generalized resistance of thyroid hormones: report of three kindreds and correlation of patterns of affected tissues with the binding of [125 I]triiodothyronine to fibroblast nuclei.","volume":"9","author":"Magner","year":"1986","journal-title":"J Endocrinol Invest"},{"key":"2020071618582238300_R9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF03350611","article-title":"Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3\u2032-triiodothyroacetic acid (TRIAC).","volume":"6","author":"Beck-Peccoz","year":"1983","journal-title":"J Endocrinol Invest"},{"key":"2020071618582238300_R10","first-page":"1034","article-title":"Evidence for the secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance.","volume":"78","author":"Persani","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618582238300_R11","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.1990.03450170093029","article-title":"Neonatal detection of generalized resistance to thyroid hormone.","volume":"264","author":"Weiss","year":"1990","journal-title":"JAMA"},{"key":"2020071618582238300_R12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1651-2227.1995.tb13639.x","article-title":"Detection of resistance to thyroid hormone by cord blood screening.","volume":"84","author":"Wong","year":"1995","journal-title":"Acta Paediatr"},{"key":"2020071618582238300_R13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2265.1988.tb03684.x","article-title":"Effects of thyroid hormones (T4, T3), bromocriptine and TRIAC on inappropriate TSH hypersecretion.","volume":"28","author":"Salmela","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618582238300_R14","first-page":"663","article-title":"Hyperthyroidism due to a familial pituitary resistance to thyroid hormone: successful control with 3,5,3\u2032 triiodothyroacetic associated to propranolol.","volume":"14","author":"Aguilar Diosdado","year":"1991","journal-title":"J Clin Invest"},{"key":"2020071618582238300_R15","first-page":"2033","article-title":"Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone.","volume":"80","author":"Takeda","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618582238300_R16","first-page":"2","volume":"1","author":"Beck-Peccoz","year":"1993"},{"key":"2020071618582238300_R17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/(SICI)1097-0223(199605)16:5<443::AID-PD892>3.0.CO;2-2","article-title":"Prenatal hypothyroidism: is there more than one option?","volume":"16","author":"Nicolini","year":"1996","journal-title":"Prenat Diagn"},{"key":"2020071618582238300_R18","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1073\/pnas.86.23.9114","article-title":"Negative regulation of the thyroid stimulating hormone \u03b1 gene by thyroid hormone: receptor interaction adjacent to the TATA box.","volume":"86","author":"Chatterjee","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071618582238300_R19","first-page":"1262","article-title":"Spectrum of transcriptional, dimerization and dominant negative properties of twenty different mutant thyroid hormone \u03b2 receptors in thyroid hormone resistance syndrome.","volume":"8","author":"Collingwood","year":"1994","journal-title":"Mol Endocrinol"},{"key":"2020071618582238300_R20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.1992.tb01444.x","article-title":"Functional properties of a novel mutant thyroid hormone receptor in a family with generalized thyroid hormone resistance syndrome.","volume":"36","author":"Adams","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618582238300_R21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0002-9378(83)90982-1","article-title":"A new procedure for fetal blood sampling in utero: preliminary results of fifty-three cases.","volume":"146","author":"Daffos","year":"1983","journal-title":"Am J Obstet Gynecol"},{"key":"2020071618582238300_R22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF03348894","article-title":"Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin.","volume":"16","author":"Persani","year":"1993","journal-title":"J Endocrinol Invest"},{"key":"2020071618582238300_R23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2265.1998.00388.x","article-title":"The development of foetal thyroid: in utero ultrasonographic measurements.","volume":"48","author":"Achiron","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618582238300_R24"},{"key":"2020071618582238300_R25","first-page":"1119","article-title":"A homozygous deletion in the C-erbA\u03b2 thyroid hormone receptor gene in a patient with generalized thyroid hormone resistance: isolation and characterization of the mutant receptor.","volume":"61","author":"Usala","year":"1991","journal-title":"Mol Endocrinol"},{"key":"2020071618582238300_R26","first-page":"2486","article-title":"Changes in the silylation degree of carbohydrate chains modify the biological properties of circulating TSH isoforms in various physiological and pathological status.","volume":"83","author":"Persani","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618582238300_R27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1210\/jcem-71-3-618","article-title":"Intrauterine diagnosis and treatment of fetal goitrous hypothyroidism.","volume":"71","author":"Perelman","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618582238300_R28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198102263040907","article-title":"Neonatal thyroid function after propylthiouracyl therapy for maternal Graves\u2019 disease.","volume":"304","author":"Cheron","year":"1981","journal-title":"N Engl J Med"},{"key":"2020071618582238300_R29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJM198607033150104","article-title":"Antithyroid drug therapy of Graves\u2019 disease during pregnancy. Optimal regimen for fetal thyroid status.","volume":"315","author":"Momotani","year":"1986","journal-title":"N Engl J Med"},{"key":"2020071618582238300_R30","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/endo.134.6.8194460","article-title":"Sialyltranferase messenger ribonucleic acid increases in thyrotrophs of hypothyroid mice: an in situ hybridization study.","volume":"134","author":"Helton","year":"1994","journal-title":"Endocrinology"},{"key":"2020071618582238300_R31","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1210\/endo.135.5.7956920","article-title":"\u03b2-1,4-galactosyltransferase and \u03b1-mannosidase-II messenger ribonucleic acid levels increase with different kinetics in thyrotrophs of hypothyroid mice.","volume":"135","author":"Helton","year":"1994","journal-title":"Endocrinology"},{"key":"2020071618582238300_R32"},{"key":"2020071618582238300_R33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199603283341310","article-title":"Prematurity-associated neurologic and developmental abnormalities and neonatal thyroid function.","volume":"28","author":"Vulsma","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071618582238300_R34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJM199603283341303","article-title":"The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age.","volume":"334","author":"Reuss","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071618582238300_R35","first-page":"1081","article-title":"Deoxyribonucleic acid binding and transcriptional silencing by a truncated c-erbA\u03b21 thyroid hormone receptor identified in a severely retarded patient with resistance to thyroid hormone.","volume":"82","author":"Behr","year":"1997","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/2\/405\/13122083\/jcem0405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/2\/405\/13122083\/jcem0405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:10:42Z","timestamp":1594959042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/84\/2\/405\/2864097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.84.2.5479","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2,1]]}}}